Nuo Therapeutics, Inc. (OTCMKTS:NUOTQ) Files An 8-K Other Events

Nuo Therapeutics, Inc. (OTCMKTS:NUOTQ) Files An 8-K Other Events
Item 8.01. Other Events.

On November 21, 2016, Nuo Therapeutics, Inc. (the “Company”) reported that the initial PACE study results were presented during a clinical session at the American Heart Association meeting in November 2016.  There were no significant differences from baseline to six months between the cell and placebo groups for the four co-primary endpoints.  Additionally, there were no significant improvements for quality of life secondary endpoints, nor correlative relationships between changes in magnetic resonance outcomes and peak walking time. Post-hoc exploratory analysis revealed ALDH bright cells were associated with an increase in the number of collateral arteries in participants with completely occluded femoral arteries.  The Company understands that the Cardiovascular Cell Therapy Research Network is seeking to have the full study results published in a cardiovascular focused peer-reviewed journal in the next several months.

It is presently unclear whether the Bright Cell technology can be further developed clinically and, if so, whether the Company would strategically pursue any such development.   As previously disclosed, the Company’s primary focus is execution of the required Coverage with Evidence Development (CED) protocols and commercial development of the AurixTM technology for chronic wounds. 

 

Cautionary Statement Regarding Forward-Looking Statements

The statements contained in this Current Report on Form 8-K that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 31E of the Securities Exchange Act of 1934, including statements regarding the Company’s expectations, hopes, beliefs, intentions, or strategies regarding the future. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. All forward-looking statements included in this document are based on information available to the Company on the date hereof and the Company assumes no obligation to update any such forward-looking statement. Prospective investors should also consult the risks described from time to time in the Company’s Reports on Forms 10-K, 10-Q and 8-K and Annual Reports to Shareholders.

The filing of this Form 8-K shall not be deemed an admission as to the materiality of any information herein.

  


About Nuo Therapeutics, Inc. (OTCMKTS:NUOTQ)

Nuo Therapeutics, Inc., formerly Cytomedix, Inc., is a regenerative therapies company developing and marketing products within the United States and internationally through its strategic partners. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company’s commercial offerings are centered on its point of care platform technologies for the separation of blood and bone marrow to produce platelet based therapies or cell concentrates. It is promoting two distinct platelet rich plasma (PRP) technologies: the Aurix System for wound care, and the Angel concentrated Platelet Rich Plasma (cPRP) System for orthopedics and cardiovascular markets. The Company is focused on developing product candidates utilizing the Bright Cell technology platform, owned by its subsidiary, Aldagen, Inc.

Nuo Therapeutics, Inc. (OTCMKTS:NUOTQ) Recent Trading Information

Nuo Therapeutics, Inc. (OTCMKTS:NUOTQ) closed its last trading session at 0.0120 with 51,009 shares trading hands.

An ad to help with our costs